MorphoSys implements Dotmatics’ Vortex to improve antibody research

Dotmatics’ Vortex will enable MorphoSys to rapidly analyse and visualise their screening data, informing the decision-making process.

Dotmatics, a leading provider of scientific informatics solutions and services, announced MorphoSys will implement Vortex to analyse and visualise their screening data enabling rapid, informed decision making. MorphoSys choose Vortex because of the intuitive nature of the product and its extensive drug discovery capabilities.

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases and is focused on creating a pipeline of biopharmaceuticals in the biotechnology industry. MorphoSys will also utilise the biologics capabilities in Vortex to support analysis of molecules within their antibody research.

The modular, comprehensive and secure platform underpins all of the informatics solutions provided by Dotmatics. The platform is a truly collaborative environment where disparate researchers can share ideas and discuss results in real time. Vortex is an intuitive and versatile solution for scientific data analysis and visualization. Alongside the ability to visualize numeric and textual data and perform statistical analysis, Vortex provides the capability for scientists to visualize scientific objects including molecules, sequences and genes, and provides cheminformatics and bioinformatics analysis methods that analyze those objects. With Vortex scientists can rapidly draw meaningful conclusions about research results, and make informed decisions about how best to progress small molecule or biologics projects.

“We had been scouting for a convenient software solution to analyze the very high number of antibody candidates selected from our Ylanthia^® phage display technology,” said Dr. Markus Enzelberger, Senior Vice President & Department Head of Discovery Alliances and Technologies at MorphoSys. “By choosing Dotmatics Vortex we expect to significantly streamline our workflows and to decrease our timelines to highly differentiated drug candidates.”

“We are delighted that MorphoSys has chosen to deploy Vortex,” said Dr Stephen Gallagher, CEO at Dotmatics. “MorphoSys is highly regarded within antibody research and we are confident that Vortex can wholly support their quest to find new and innovative treatments for patients suffering from serious diseases. Dotmatics’ informatics solutions and support services are vital to the success of many biotech companies who rely on Dotmatics solutions to enable global collaboration in the development of new therapies and treatments.”